260 related articles for article (PubMed ID: 37559413)
1. A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab.
Bracchi P; Zecca E; Brunelli C; Miceli R; Tinè G; Maniezzo M; Lo Dico S; Caputo M; Shkodra M; Caraceni AT
Cancer Med; 2023 Sep; 12(17):18317-18326. PubMed ID: 37559413
[TBL] [Abstract][Full Text] [Related]
2. Medication-Related Osteonecrosis of the Jaw in Cancer Patients: Result from the OneFlorida Clinical Research Consortium.
Yang G; Williams R; Wang L; Farhadfar N; Chen Y; Loiacono AT; Bian J; Holliday LS; Katz J; Gong Y
J Bone Miner Res; 2022 Dec; 37(12):2466-2471. PubMed ID: 36151778
[TBL] [Abstract][Full Text] [Related]
3. A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis.
Campisi G; Mauceri R; Bertoldo F; Fusco V; Bedogni A
Head Face Med; 2021 Jul; 17(1):25. PubMed ID: 34243807
[TBL] [Abstract][Full Text] [Related]
4. Immune Dysfunction in Medication-Related Osteonecrosis of the Jaw.
Roato I; Mauceri R; Notaro V; Genova T; Fusco V; Mussano F
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175652
[TBL] [Abstract][Full Text] [Related]
5. Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ).
Otto S; Aljohani S; Fliefel R; Ecke S; Ristow O; Burian E; Troeltzsch M; Pautke C; Ehrenfeld M
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34065104
[TBL] [Abstract][Full Text] [Related]
6. Interventions for managing medication-related osteonecrosis of the jaw.
Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
[TBL] [Abstract][Full Text] [Related]
7. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
Cancer Chemother Pharmacol; 2021 Jun; 87(6):871-877. PubMed ID: 33791853
[TBL] [Abstract][Full Text] [Related]
8. A nested case-control study of factors contributing to the development of medication-related osteonecrosis of the jaw in patients using bone resorption inhibitors in Mishima City.
Seki K; Kamimoto A; Wada M; Iinuma T
J Oral Sci; 2023 Jul; 65(3):184-189. PubMed ID: 37245962
[TBL] [Abstract][Full Text] [Related]
9. Risk of medication-related osteonecrosis of the jaw after dental extractions in patients receiving antiresorptive agents - A retrospective study of 240 patients.
Coropciuc R; Coopman R; Garip M; Gielen E; Politis C; Van den Wyngaert T; Beuselinck B
Bone; 2023 May; 170():116722. PubMed ID: 36858337
[TBL] [Abstract][Full Text] [Related]
10. Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).
Aguirre JI; Castillo EJ; Kimmel DB
Bone; 2021 Dec; 153():116184. PubMed ID: 34520898
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Medication-Related Osteonecrosis of the Jaw: Controversies in Causality and Therapy.
Halpern LR; Adams DR
Dent Clin North Am; 2024 Jan; 68(1):67-85. PubMed ID: 37951638
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
Soutome S; Hayashida S; Funahara M; Sakamoto Y; Kojima Y; Yanamoto S; Umeda M
PLoS One; 2018; 13(7):e0201343. PubMed ID: 30048523
[TBL] [Abstract][Full Text] [Related]
13. A Study of Oral Health Parameters and the Properties and Composition of Saliva in Oncological Patients with and without Medication-Related Osteonecrosis of the Jaw Who Take Bisphosphonates.
Sobczak-Jaskow H; Kochańska B; Drogoszewska B
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374277
[No Abstract] [Full Text] [Related]
14. Case series of medication-related osteonecrosis of the jaw (MRONJ) patients prescribed a drug holiday.
Hamid A; Thomas S; Bell C; Gormley M
Br J Oral Maxillofac Surg; 2023 Apr; 61(3):227-232. PubMed ID: 36935312
[TBL] [Abstract][Full Text] [Related]
15. Etiopathogenesis of medication-related osteonecrosis of the jaws: a review.
Bassan Marinho Maciel G; Marinho Maciel R; Linhares Ferrazzo K; Cademartori Danesi C
J Mol Med (Berl); 2024 Mar; 102(3):353-364. PubMed ID: 38302741
[TBL] [Abstract][Full Text] [Related]
16. Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan.
Liu FC; Luk KC; Chen YC
Osteoporos Int; 2023 Oct; 34(10):1729-1737. PubMed ID: 37326685
[TBL] [Abstract][Full Text] [Related]
17. In Vitro Cytotoxicity of Antiresorptive and Antiangiogenic Compounds on Oral Tissues Contributing to MRONJ: Systematic Review.
Guirguis RH; Tan LP; Hicks RM; Hasan A; Duong TD; Hu X; Hng JYS; Hadi MH; Owuama HC; Matthyssen T; McCullough M; Canfora F; Paolini R; Celentano A
Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371553
[TBL] [Abstract][Full Text] [Related]
18. Survey of the association between tooth extraction and development of medication-related osteonecrosis of the jaw in patients undergoing cancer treatment with bone-modifying agents.
Nozawa-Kobayashi M; Sakuma H; Kanemaru H; Kurokawa A; Soga M; Yamashita M; Niimi K; Kobayashi T
Oral Maxillofac Surg; 2024 Jun; 28(2):849-857. PubMed ID: 38296902
[TBL] [Abstract][Full Text] [Related]
19. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
Ikesue H; Mouri M; Tomita H; Hirabatake M; Ikemura M; Muroi N; Yamamoto S; Takenobu T; Tomii K; Kawakita M; Katoh H; Ishikawa T; Yasui H; Hashida T
Support Care Cancer; 2021 Aug; 29(8):4763-4772. PubMed ID: 33527228
[TBL] [Abstract][Full Text] [Related]
20. MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series.
Mauceri R; Coppini M; Attanasio M; Bedogni A; Bettini G; Fusco V; Giudice A; Graziani F; Marcianò A; Nisi M; Isola G; Leonardi RM; Oteri G; Toro C; Campisi G
BMC Oral Health; 2023 Feb; 23(1):71. PubMed ID: 36739399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
